

Anais: II Seminário de Iniciação Científica

EXPECTATIVAS DESAFIADORAS: Um Caso de Carcinoma Ovariano Seroso de Alto Grau em Paciente Jovem com Mutações Inesperadas

CHALLENGING EXPECTATIONS: A Case Of High-Grade Serous Ovarian Carcinoma In A Young Patient With Unexpected Mutations

Stephanie Braga Gonçalves da Silva
Faculdade de Ciências Médicas de Minas Gerais.
Bolsista de Iniciação Científica do Instituto Mário Penna/FAPEMIG.
0009-0001-3650-998X
e-mail: stephanie.bragasilva@gmail.com

Paulo Guilherme de Oliveira Salles
Instituto Mário Penna – Serviço de Anatomia Patológica e Núcleo de Ensino, Pesquisa e Inovação (NEPI).
0000-0001-8839-3941
e-mail: paulo.salles@mariopenna.org.br

Iracema Maria Ribeiro da Fonseca
Instituto Mário Penna – Serviço de Ginecologia Oncológica.
0009-0002-5902-7534
e-mail: iracemafonseca1@gmail.com

Thalia Rodrigues de Souza Zozimo
Instituto Mário Penna – Núcleo de Ensino, Pesquisa e Inovação (NEPI).
0000-0001-8473-2548
e-mail: trs.liia@gmail.com

Débora Cristina de Freitas Batista
Instituto Mário Penna – Núcleo de Ensino, Pesquisa e Inovação (NEPI).
0009-0004-9532-1305
e-mail: deboracfbatista@gmail.com

Carolina Pereira de Melo
Instituto Mário Penna – Núcleo de Ensino, Pesquisa e Inovação (NEPI).
0000-0001-9698-5817
e-mail: deboracfbatista@gmail.com

Data de submissão: 17/06/2024.

Data de aprovação: 18/06/2024.

RESUMO

Despite the low prevalence, ovarian cancer has high mortality. More common in elderly patients, is mostly diagnosed late, which leads to high recurrence and a low five-years-disease-free-survival. Carcinoma is the most common type, and the high grade serous carcinoma (HGSC) subtype stands out in terms of aggressiveness. Whereas genetic mutations would be responsible for this difference, it was proposed a tumor classification model, which considers the main genetic changes found. Here we describe the genetic associations observed in young patient with HGSC and her clinical outcome.

Palavras-chave: câncer de ovário; mutação; testes genéticos; relatos de casos.

REFERÊNCIAS

1. Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. [Updated 2023 Jun 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK567760/>.

2. Zamwar UM, Anjankar AP. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. *Cureus*. 2022;14(10):e30561. doi: 10.7759/cureus.30561.
3. McLemore MR, Miaskowski C, Aouizerat BE, et al. Epidemiological and genetic factors associated with ovarian cancer. *Cancer Nurs*. 2009;32(4):281-8; quiz 289-90. doi: 10.1097/NCC.0b013e31819d30d6.
4. Bunde S, Baskota SU, Fine J, et al. Educational Case: High-Grade Serous Carcinoma of the Ovary. *Acad Pathol*. 2021;8:23742895211032339. doi: 10.1177/23742895211032339.
5. Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. *Am J Pathol*. 2016;186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011.
6. Boyarskikh UA, Gulyaeva LF, Avdalyan AM, et al. Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer. *Front Oncol*. 2020;10:1103. doi: 10.3389/fonc.2020.01103.
7. Chui MH, Momeni Boroujeni A, Mandelker D, et al. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. *Mod Pathol*. 2021;34(2):490-501. doi: 10.1038/s41379-020-00648-y.
8. Zeissig MN, Ashwood LM, Kondrashova O, et al. Next batter up! Targeting cancers with KRAS-G12D mutations. *Trends Cancer*. 2023; 9(11):955-967. doi: 10.1016/j.trecan.2023.07.010.
9. Vang R, Levine DA, Soslow RA, et al. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. *Int J Gynecol Pathol*. 2016;35(1):48-55. doi: 10.1097/PGP.0000000000000207.
10. Vergote I, Denys H, De Greve J, et al. Treatment algorithm in patients with ovarian cancer. *Facts Views Vis Obgyn*. 2020;12(3):227-239. PMID: 33123697.
11. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. *Ther Adv Med Oncol*. 2014;6(5):229-39. doi: 10.1177/1758834014544121.
12. Tuna M, Ju Z, Yoshihara K, et al. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. *Br J Cancer*. 2020;122(3):405-412. doi: 10.1038/s41416-019-0654-8.
13. Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? *Int J Mol Sci*. 2020;21(3):1128. doi: 10.3390/ijms21031128.
14. Punzón-Jiménez P, Lago V, Domingo S, Simón C, Mas A. Molecular Management of High-Grade Serous Ovarian Carcinoma. *Int J Mol Sci*. 2022;23(22):13777. doi: 10.3390/ijms232213777.
15. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-24. doi: 10.1038/gim.2015.30.
16. Yamulla RJ, Nalubola S, Flesken-Nikitin A, et al. Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation. *Cell Rep*. 2020;32(9):108086. doi: 10.1016/j.celrep.2020.108086.
17. Berek JS, Rens M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *Int J Gynaecol Obstet* 2021;155:61–85. <https://doi.org/10.1002/ijgo.13878>.

Agradecimentos e Suporte Financeiro: Fundação de Amparo à Pesquisa do Estado de Minas Gerais – FAPEMIG.